Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 11,400 shares of Opko Health stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average cost of $9.09 per share, with a total value of $103,626.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $18,292,507. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on OPK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Opko Health (NYSE:OPK) traded up 0.50% on Monday, hitting $9.125. The stock had a trading volume of 359,816 shares. Opko Health has a 1-year low of $7.32 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.91 and a 200-day moving average of $8.80. The company’s market cap is $3.916 billion.

Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. Analysts expect that Opko Health will post $-0.33 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.